Acerus Pharmaceuticals Corporation announced that, effective July 1, 2021, an additional leading pharmacy benefit manager (PBM) in the United States has elected to make NATESTO® (testosterone nasal gel) a “Preferred Brand” on its National Preferred Drug List. Drugs listed on formulary as preferred brands have been evaluated by the PBM from a therapeutic and value perspective. Preferred branded drugs may be available to patients at a lower co-pay or co-insurance than non-preferred brand drugs.